Fluconazole-induced Stevens-Jonson syndrome

Umashanker P. Keshri, Naresh Kumar, Rajiv Kumar, Manju Gari


A 25-year-old girl self-administered tab fluconazole for vulvovaginal candidiasis and developed fever, myalgia and erythematous papular eruptions with itching at both upper and lower lip, mucous membrane of the mouth, vaginal region, which subsequently changed into blister and multiple ulcers. She also had difficulty in swallowing due to painful erosions of the mouth and oropharynx and severe burning pain at vulval and vaginal region. There was bilateral conjunctival hemorrhage. Investigation report revealed leukocytosis and elevated C-reactive protein, which was suggesting the diagnosis of Stevens-Johnson syndrome. She was treated mainly by corticosteroids, antihistamines and antimicrobials and improved. Time taken for resolution of the lesion was 14 days. Rechallenge with the offending drug was not done in the interest of the patient and due to ethical constraints.


Fluconazole, Papular eruptions, Stevens-Johnson syndrome

Full Text:



Brockmeyer NH, Tillmann I, Mertins L, Barthel B, Goos M. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur J Med Res. 1997;2(9):377-83.

Pappas PG, Kauffman CA, Perfect J, Johnson PC, McKinsey DS, Bamberger DM, et al. Alopecia associated with fluconazole therapy. Ann Intern Med. 1995;123(5):354 7.

Stevens DA, Diaz M, Negroni R, Montero-Gei F, Castro LG, Sampaio SA, et al. Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group. Chemotherapy. 1997;43(5):371-7.

Anaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE, Karl C, Prince RA, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis. 1995;172(2):599-602.

Gussenhoven MJ, Haak A, Peereboom-Wynia JD, van’t Wout JW. Stevens-Johnson syndrome after fluconazole. Lancet. 1991;338(8759):120.

Gearhart MO. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother. 1994;28(10):1177-81.

Villada G, Roujeau JC, Clérici T, Bourgault I, Revuz J. Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol. 1992;128(1):50-3.

French L, Prins C. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. Philadelphia PA: Elsevier; 2008:287-300.

Teraki Y, Shibuya M, Izaki S. Stevens-Johnson Syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with Drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations. Clin Exp Dermatol. 2010;35(7):723-8.

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255 9.

Magee P. Drug induced skin disorders. In: Walker R, Edwards C, editors. Clinical Pharmacy and Therapeutics. 2nd Edition. London: Churchill Livingstone; 1999: 837.

Frosch DL, Grande D. Direct-to-consumer advertising of prescription drugs. LDI Issue Brief. 2010;15(3):1-4.